

67 transaminase (ALT) 139U/l, aspartate transaminase (AST)
68 317 U/l), and hyponatremia (132 mmol/l).

69 Chest computed tomography (CT)-scan (Figure 1)
70 found bilateral ground-glass opacities (GGOs) and bilat-
71 eral lower lobe consolidation.

72 On intensive care unit (ICU) admission, the echocardi-
73 ogram showed an increase in pulmonary vascular resist-
74 ance with acute pulmonary hypertension associated with
75 right ventricle dysfunction. During hospitalization, ECG
76 revealed an intermittent first-degree atrioventricular block
77 associated with elevated cardiac biomarkers on blood tests
78 suggesting myocarditis (Table 1). This hypothesis was
79 confirmed on delayed cardiac magnetic resonance imag-
80 ing (MRI) (Figure 2).

81 Virological molecular analysis with real-time reverse
82 transcription-polymerase chain reaction (RT-PCR) on
83 nasopharyngeal swab, broncho-alveolar lavage (BAL),
84 and bloodstream were positive for HAdV with viral loads
85 on BAL and bloodstream of 7,75 log copies/ml and > 9
86 log copies/ml, respectively.

87 *Differential diagnosis*

88 Bacteriological and mycological tests on blood, urine, and
89 BAL samples were repeatedly negative.

90 Autoimmune disease and immunodeficiency were
91 ruled out. Initial lymphopenia and hypogammaglobuline-
92 mia were normalized on discharge.

93 *Treatment*

94 The initial antibiotic therapy consisted of an association
95 of CEFOTAXIM and SPIRAMYCIN rapidly switched
96 to PIPERACILLIN/TAZOBACTAM and LINEZOLID
97 because of worsening respiratory symptoms and multi-or-
98 gan failure (MOF) including hemodynamic instability and
99 kidney failure. She was intubated and transferred to the
100 ICU. She required vasopressor support up to 0.5 µg/Kg/
101 minute of NOREPINEPHRINE and renal replacement

therapy at day 7. After prone positioning failure, veno-ve- 102
nous extra corporal membrane oxygenation (ECMO) 103
support was initiated in the case of refractory acute respi- 104
ratory failure on day 8. 105

Outcome and follow-up

ECMO was weaned three days later and she was extu- 106
bated 2 weeks after admission. 107

Clinical symptoms and bloodstream viremia under- 108
went a parallel evolution. No viremia was detectable 109
when she was discharged. A follow-up chest CT scan on 110
day 26 showed some remaining consolidation and pleural 111
effusion with a significant viral load on BAL and pleural 112
puncture (Table 1). 113

114
115 She was off oxygen 7 days after extubation and
116 then transferred to a respiratory ward for pulmonary
117 rehabilitation.

118 After a week in the respiratory ward, she was dis-
119 charged from the hospital.

120 A few months later, a follow-up cardiac MRI showed
121 complete recovery of the heart, and a chest X-ray showed
122 her lung tissue had returned to normal.

Case 2

123
124 A 45-year-old man with a medical history of chronic
125 hypertension, 20 pack-year smoking, and chronic alco-
126 hol consumption, presented an influenza-like syndrome
127 revealed by fever, cough, asthenia, myalgia, and diarrhea.
128 Seven days later, he was admitted to the ED for worsening
129 symptoms and dyspnea.

130 On arrival, vital signs were as follows: body tempera-
131 ture 38°C, systemic arterial blood pressure 90/50 mmHg,
132 heart rate 120 /minute, and SpO₂ 90% on room air.

Investigations

133 Laboratory investigations on admission revealed severe
134 inflammation, acute kidney injury (serum creatinine 4.7
135 mg/dl, blood urea nitrogen 1.5 g/l), lymphopenia (<0,1
136 × 10⁹/l), liver cytolysis (AST 372 U/l, SGPT 52 U/l),
137 rhabdomyolysis (CPK 2730 U/l), myocardial injury with
138 increased high-sensitive cardiac troponin T level in the
139 plasma (140 ng/l), and hyponatremia (132 mmol/l). 140

141 Chest X-ray (Figure 3) showed severe pulmonary infil-
142 trates and CT scan (Figure 4) found severe bilateral con-
143 solidations and GGO.

144 The microbiological assessment did not reveal any
145 bacterial or fungal infection. The only microbiologic
146 result was a positive HAdV RT-PCR in the BAL and
147 bloodstream (>8.00 Log copies/ml).

Treatment





148 The initial antimicrobial therapy consisted of an associa-
149 tion of CEFOTAXIM and LEVOFLOXACIN. 150

151 The outcome was initially similar to case 1 with MOF
152 and refractory acute respiratory failure requiring veno-ve-
153 nous ECMO support on day 1 after ICU admission.



154
155 **Figure 1.** Initial CT-scan revealing bilateral posterior consolidation (A) and anterior GGO (B). GGO: ground-glass opacities.
156

157 **Table 1.** Evolution of different organ dysfunctions according to human adenovirus (HAdV) loads in patient 1. ECMO: Extra-Corporeal
 158 Membrane oxygenation, APRV: Airway Pressure Release Ventilation, VC: Volume controlled ventilation, FIO₂: Fraction of inspired
 159 Oxygen, FmO₂: Membrane fraction of oxygen, P-high: highest level of pressure applied, P-low: lowest level of pressure applied, PEEP:
 160 Positive End-Expiratory Pressure, cmH₂O: centimetre of water, NO: Nitric Oxide, ppm: parts per million, CVVH: Continuous Veino-
 161 Veinous Hemofiltration, RV: Right Ventricle, AVB: Atrio-Ventricular Block, PAP: Pulmonary Artery Pressure, TAPSE: Tricuspid Annular
 162 Plane Systolic Excursion, S-DTI: tricuspid annular S' wave on Doppler Tissue Imaging, BAL: Broncho-Alveolar Lavage, N: normal, CC:
 163 Creatinine clearance. CC was calculated by the following formula: $(U \cdot V) / (p \cdot 1440)$, where U is the number of milligrams of creatinine in
 164 each deciliter of urine within 24 hours; V is the volume of urine output per minute in milliliters; P is the serum creatinine in milligrams per
 deciliter.

DAYS SINCE ICU ADMISSION	DAY 1	DAY 7	DAY 20	DAY 26
Respiratory support	- ECMO FmO ₂ : 100% - Mechanical ventilation APRV FiO ₂ : 90% P-high: 20 cmH ₂ O P-low: 8 cmH ₂ O - Added NO 10 ppm	- OFF ECMO - Mechanical ventilation VC FiO ₂ : 40% PEEP: 10 cmH ₂ O - OFF NO	- OFF Mechanical ventilation - 4 l/minute oxygen nasal cannula	- On room air
Lung				
Liver	Cytolysis ALT : 186 UI/L AST : 627 UI/L N : 10-35 UI/L	Cytolysis ALT : 153 UI/L AST : 199 UI/L N : 10-35 UI/L	Cytolysis ALT : 111 UI/L AST : 124 UI/L N : 10-35 UI/L	Cytolysis ALT : 68 UI/L AST : 114 UI/L N : 10-35 UI/L
Kidney	CVVH	Urine output recovery CC = 37 ml/minute	Full recovery CC = 63 ml/minute	Full recovery CC = 81 ml/minute
Hemodynamic	Norepinephrine up to 0.5 µg/Kg/minute	OFF Norepinephrine	OFF Norepinephrine	OFF Norepinephrine
Heart	RV dysfunction (TAPSE 15 mm, S-DTI 9 cm/s) Elevated PAP (PAPS 55 mmHg) Normal ECG Troponin T us 300 ng/l (N : < 14 ng/l)	RV dysfunction (TAPSE 16 mm, S-DTI 10 cm/s) Elevated PAP (PAPS 35 mmHg) 1st degree AV block Troponin T us 45 ng/l (N : < 1 4 ng/l)	Normalised RV (TAPSE 21 mm, S-DTI 12 cm/s) Normalised PAP (PAPS 27 mmHg) Normal ECG	Normalised RV (TAPSE 25 mm, S-DTI 15 cm/s) Normalised PAP (PAPS 27 mmHg) Normal ECG
HAdV RT-PCR Viral Load (Log copies/ml)	No data	Bloodstream : > 9 log copies/ml BAL : 7.75 log copies/ml	No data	Bloodstream : - day 26 : 1.32 log copies/ml - day 29 : undetectable BAL : 5.43 log copies/ml Pleural : 3.57 log copies/ml


165 Outcome

166 Eventually, the patient developed a type three atrioventricular block with extreme bradycardia revealing an
 167 acute coronary syndrome. The coronary angiogram displayed an occlusion of the left coronary artery. Although
 168 a coronary angioplasty was performed on the causal artery, the patient presented a refractory cardiac arrest.
 169 Despite receiving cardiopulmonary resuscitation and being upgraded to veno-veno-arterial ECMO support, the
 170 patient died on day 3.


175 Microbiological assessment

176 Samples of the HAdV were sent to Saint-Louis Hospital in Paris for strain genotyping. Both strains were identified
 177 as HAdV-B7d.


178 There was no evidence that the 2 patients had been in contact with each other or shared any common friends or
 179 family members. They lived in different cities in northern France. There was no indication of a common cluster of
 180 HAdV infections.



184
185 **Figure 2.** CMR showed areas of edema in inferolateral, mid-cav-
186 itary, and basal positions in T2 parametric imaging in favor of
187 edema.



188
189 **Figure 4.** Initial CT scan revealing bilateral anterior GGO (A) and
190 posterior consolidations (B). GGO: ground-glass opacities.



191
192 **Figure 3.** Initial Chest X-ray with bilateral pulmonary infiltrates.

193 **Discussion**

194 Several serious HAdV outbreaks have been reported in
195 the last years all over the world [3-6]. To date, only a few
196 severe HAdV cases have been isolated in France [5], none
197 with the B7d genotype. This HAdV B7d genotype has
198 been identified in patients with severe acute respiratory
199 failure in the USA [3,10,11] and China [12] since 2013.
200 Our case report highlights the emergence of HAdV-B7d
201 genotype-related acute respiratory distress syndrome
202 (ARDS) in young adults on the French territory.

203 Given the uncommon nature of these infections, they
204 could be underdiagnosed if viral screening is not available
205 or if positive tests are not considered clinically relevant.
206 These two case reports showed the importance of screen-
207 ing for viral pneumonias especially when no obvious
208 infectious agent is identified or could explain the clinical
209 picture. If blood or respiratory samples are positive for
210 Adenovirus, then we should consider an HAdV infection

211 as a potential cause of severe ARDS, even in a young
212 immunocompetent adult patient [10].

213 In our two patients, the initial severity may be associ-
214 ated with very high viral loads in bloodstream and BAL.
215 Moreover, a decrease in viral load was associated with a
216 good clinical evolution in patient one. We suggest that in
217 severe forms of HAdV-related infections, initial assess-
218 ment and kinetics of viral load in blood samples or BAL
219 could help clinicians predict patients' outcomes and guide
220 therapeutic decisions.

221 Our clinical experience further highlights the neces-
222 sity of cardiac monitoring for severe cardiac complica-
223 tions related to HAdV-B7d infections. Myocardial injury
224 related to HAdV was not described in most case reports,
225 but like many other viral infections, HAdV could be asso-
226 ciated with myocarditis with a large spectrum of clini-
227 cal symptoms (arrhythmias, AV blocks, acute coronary
228 syndrome-like, ventricular dysfunction, and so on) [13].
229 HAdV was described in rare cases to be associated with
230 pericarditis with pericardial effusion [14].

231 There are no validated treatments for HAdV, sev-
232 eral molecules have been tested in immunocompromised
233 patients, including IV immunoglobulin, RIBAVIRIN,
234 GANCICLOVIR, and CIDOFOVIR [1]. CIDOFOVIR is
235 a broad-spectrum antiviral drug. CIDOFOVIR is a nucle-
236 oside phosphonate analogue with proven action against all
237 serotypes of HAdV [15]. CIDOFOVIR had a broader anti-
238 viral spectrum on HAdV *in vitro* than other antivirals such
239 as RIBAVIRIN [15]. CIDOFOVIR is proposed as the first-
240 line treatment of severe HAdV infections. We have not used
241 this treatment in patient 1 because of her positive evolution.
242 Patient 2 died rapidly before initiating the treatment.

243 Eventually, the HAdV-B7 vaccine is available and used
244 in the US military because of several severe cases in this
245 particular population [9]. Vaccination is an alternative
246 strategy in case of a HAdV endemic spread. Nevertheless,
247 most epidemics were described in children or military

248 troops [6-8], and none in adult civilians, which makes it a
249 less plausible option.

250 Conclusion

251 Viral pneumonias are often underdiagnosed, which com-
252 plicates treatment. HAdV infections can cause severe
253 ARDS and multi-organ failure in young, non-immu-
254 nocompromised adults, highlighting the importance of
255 cardiac monitoring due to potential myocardial complica-
256 tions. Assessing viral load in initial blood or BAL samples
257 and tracking changes over time can help predict outcomes
258 and guide treatment decisions, improving patient care.

259 What is new?

260 Viral pneumonias are frequently under-diagnosed. Human
261 adenovirus infections can cause severe acute respiratory
262 distress syndrome with multi-organ failure in young non-im-
263 munocompromised adults including severe myocardial
264 complications. Assessment of viral load in initial blood or
265 BAL samples, and monitoring changes over time, may help
266 clinicians predict patient outcomes and guide treatment
267 decisions.

268 List of Abbreviations

269	AST	Aspartate Transaminase
270	BAL	Broncho-Alveolar Lavage
271	CT	Computed tomography
272	ED	Emergency department
273	GGO	Ground-glass opacities
274	HAdV	Human adenovirus
275	ICU	Intensive care unit
276	MRI	Magnetic resonance imaging
277	RT-PCR	Reverse transcription-polymerase chain reaction

278 Conflict of interests

279 The authors declare that there is no conflict of interest regard-
280 ing the publication of this case report.

281 Funding

282 None.

283 Consent for publication

284 Written informed consent was obtained from the patient.

285 Ethical approval

286 Ethical approval is not required at our institution to publish an
287 anonymous case report.

288 Author details

289 Ghadi Zebian¹, Aurelie Guigon², Christos Gkizas³, Sebastien
290 Preau^{1,4}, Arthur Durand¹

- 291 1. CHU Lille, Service de Médecine Intensive - Réanimation, Lille,
292 France
- 293 2. CHU de Lille, Laboratoire de Virologie, Centre de Biologie
294 Pathologie, Lille, France
- 295 3. CHU de Lille, Service de Radiologie, Lille, France
- 296 4. Département Médecine, CHU Lille, Institut Pasteur de Lille,
297 Lille, France

References

- 298 1. Ison MG. Adenovirus infections in transplant recipi- 299
300 ents. *Clin Infect Dis*. 2006 Aug;43(3):331–9. <https://doi.org/10.1086/505498> 301
- 302 2. Yeung R, Eshaghi A, Lombos E, Blair J, Mazzulli T, Burton 303
304 L, et al. Characterization of culture-positive adenovi- 305
306 rus serotypes from respiratory specimens in Toronto, 307
308 Ontario, Canada. *Virology*. 2009 Jan;6(1):11. <https://doi.org/10.1186/1743-422X-6-11> 309
- 310 3. Scott MK, Chommanard C, Lu X, Appelgate D, Grenz L, 311
312 Schneider E, et al. Human adenovirus associated with 313
314 severe respiratory infection, Oregon, USA, 2013-2014. 315
316 *Emerg Infect Dis*. 2016 Jun;22(6):1044–51. <https://doi.org/10.3201/eid2206.151898> 317
- 318 4. Zhang SY, Luo YP, Huang DD, Fan H, Lu QB, Wo Y, et al. 319
320 Fatal pneumonia cases caused by human adenovi- 321
322 rus 55 in immunocompetent adults. *Infect Dis (Lond)*. 323
324 2016;48(1):40–7. <https://doi.org/10.3109/23744235.2015.1055585> 325
- 326 5. Lafolie J, Mirand A, Salmona M, Lautrette A, Archimbaud 327
328 C, Brebion A, et al. Severe Pneumonia associated with 329
330 adenovirus type 55 infection, France, 2014. *Emerg Infect 331*
332 *Dis*. 2016 Nov;22(11):2012–4. <https://doi.org/10.3201/eid2211.160728> 333
- 334 6. Ryan MA, Gray GC, Smith B, McKeehan JA, Hawksworth 335
336 AW, Malasig MD. Large epidemic of respiratory illness 337
338 due to adenovirus types 7 and 3 in healthy young adults. 339
340 *Clin Infect Dis*. 2002 Mar;34(5):577–82. <https://doi.org/10.1086/338471> 341
- 342 7. Erdman DD, Xu W, Gerber SI, Gray GC, Schnurr D, 343
344 Kajon AE, et al. Molecular epidemiology of adenovirus 345
346 type 7 in the United States, 1966-2000. *Emerg Infect 347*
348 *Dis*. 2002 Mar;8(3):269–77. <https://doi.org/10.3201/eid0803.010190> 349
- 350 8. Jeon K, Kang CI, Yoon CH, Lee DJ, Kim CH, Chung YS, et al. 351
352 High isolation rate of adenovirus serotype 7 from South 353
354 Korean military recruits with mild acute respiratory dis- 355
356 ease. *Eur J Clin Microbiol Infect Dis*. 2007 Jul;26(7):481–3. 357
358 <https://doi.org/10.1007/s10096-007-0312-6> 359
- 360 9. Lynch JP 3rd, Kajon AE. Adenovirus: epidemiol- 361
362 ogy, global spread of novel serotypes, and advances 363
364 in treatment and prevention. *Semin Respir Crit 365*
366 *Care Med*. 2016 Aug;37(4):586–602. <https://doi.org/10.1055/s-0036-1584923> 367
- 368 10. Killerby ME, Rozwadowski F, Lu X, Caulcrick-Grimes M, 369
370 McHugh L, Haldeman AM, et al. Respiratory illness asso- 371
372 ciated with emergent human adenovirus genome type 373
374 7d, New Jersey, 2016-2017. *Open Forum Infect Dis*. 2019 375
376 Jan;6(2):ofz017. <https://doi.org/10.1093/ofid/ofz017> 377
- 378 11. Lamson DM, Kajon A, Popowich M, Fuschino M, St George 379
380 K. Human adenovirus 7d strains associated with influen- 381
382 za-like illness, New York, USA, 2017-2019. *Emerg Infect 383*
384 *Dis*. 2020 May;26(5):1047–9. <https://doi.org/10.3201/eid2605.200116> 385
- 386 12. Zhao S, Wan C, Ke C, Seto J, Dehghan S, Zou L, et al. 387
388 Re-emergent human adenovirus genome type 7d caused 389
390 an acute respiratory disease outbreak in Southern 391
392 China after a twenty-one year absence. *Sci Rep*. 2014 393
394 Dec;4(1):7365. <https://doi.org/10.1038/srep07365> 395
- 396 13. Schultheiss HP, Baumeier C, Aleshcheva G, Bock CT, 397
398 Escher F. Viral myocarditis-from pathophysiology to treat- 399
400 ment. *J Clin Med*. 2021 Nov;10(22):5240. <https://doi.org/10.3390/jcm10225240> 401
- 402 14. Lin L, Xu M, Zhang H. Assistance of metagenomics next-gen- 403
404 eration sequencing for diagnosis of adenovirus pericardi- 405
406 tis with pericardial effusion in a child: a case report and 407

364 literature review. *Front Pediatr*. 2023 Jun;11:1174326. of adenovirus to antiviral drugs is species-depend- 368
 365 <https://doi.org/10.3389/fped.2023.1174326> ent. *Antivir Ther*. 2005;10(2):225–9. [https://doi.](https://doi.org/10.1177/135965350501000204) 369
 366 15. Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, org/10.1177/135965350501000204 370
 367 Carrington D, Sedlacek P, et al. In vitro susceptibility

Summary of the case

1	Patient (gender, age)	27 years, female (case 1) and 45 years, male (case 2)
2	Final diagnosis	Severe Adenovirus (AdV) infection
3	Symptoms	Respiratory failure, circulatory failure, renal failure
4	Medications	Symptomatic organ support, antiviral treatment : CIDOFOVIR
5	Clinical procedure	Mechanical ventilation, VV-ECMO, vasopressors, dialysis
6	Specialty	Critical care, infectious disease, virology